Aldeyra Reports Positive Mid-Stage Data For Liver Drug, Discontinues Further Development

• ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study.
• Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company said. 
• The company has, however,  now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome. 
   

Aldeyra Therapeutics, Inc. (ALDX) on Tuesday announced that its experimental drug candidate ADX-629 demonstrated statistically significant improvement in liver function in patients with alcohol-associated hepatitis in a mid-stage trial.

ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study. Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company said.

No serious adverse events were reported in the trial, the company noted. Furthermore, no adverse events were deemed related to its experimental drug, it added.

Plans Ahead

The company has, however,  now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome, a rare genetic disorder.

CEO Todd C. Brady said that the company will share details of the recent trial in the future and will now focus its pipeline on ADX-248 and ADX-246 for the treatment of immune-mediated diseases.

While ADX-248 is being studied in the treatment of metabolic inflammation, including obesity and hypertriglyceridemia, ADX-246 is being studied for the treatment of dry form of age-related macular degeneration.

Aldeyra is committed to developing a robust pipeline of novel therapeutics in a fiscally prudent manner to maintain growth, the CEO noted.

The company now expects cash, cash equivalents, and marketable securities to provide operational runway into the second half of 2027.

How Did Stocktwits Users React?

On Stocktwits, retail sentiment around ALDX stock jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.

ALDX stock is down by 0.5% this year and by about 12% over the past 12 months. 

Read also: Tesla Registrations Slumped Nearly 19% In EU In September Despite Rising EV Demand

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on